EUVIMEDEUVIMED entdecken
Crossref

Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer

Lisha Bao, Ying Li, Xiaoping Hu, Yingying Gong, Jinming Chen, Ping Huang, Zhuo Tan, Minghua Ge, Zongfu Pan

International Immunopharmacology · 2024-05 · 133 · 112102

DOI: 10.1016/j.intimp.2024.112102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-05. Verfasst von Lisha Bao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's…. Hauptthemen laut MEDLINE: Immunotherapy, Membrane Proteins, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic thyroid carcinoma (ATC) is the most aggressive subtype of thyroid cancer with few effective therapies. Though immunotherapies such as targeting PD-1/PD-L1 axis have benefited patients with solid tumor, the druggable immune checkpoints are quite limited in ATC. In our study, we focused on the anti-tumor potential of sialic acid-binding Ig-like lectins (Siglecs) in ATC. Through screening by integrating microarray datasets including 216 thyroid-cancer tissues and single-cell RNA-sequencing, SIGLEC family members CD33, SIGLEC1, SIGLEC10 and SIGLEC15 were significantly overexpressed in ATC, among which SIGLEC15 increased highest and mainly expressed on cancer cells. SIGLEC15high ATC cells are characterized by high expression of serine protease PRSS23 and cancer stem cell marker CD44. Compared with SIGLEC15low cancer cells, SIGLEC15high ATC cells exhibited higher interaction frequency with tumor microenvironment cells. Further study showed that SIGLEC15high cancer cells mainly interacted with T cells by immunosuppressive signals such as MIF-TNFRSF14 and CXCL12-CXCR4. Notably, treatment of anti-SIGLEC15 antibody profoundly increased the cytotoxic ability of CD8+ T cells in a co-culture model and zebrafish-derived ATC xenografts. Consistently, administration of anti-SIGLEC15 antibody significantly inhibited tumor growth and prolonged mouse survival in an immunocompetent model of murine ATC, which was associated with increase of M1/M2, natural killer (NK) cells and CD8+ T cells, and decrease of myeloid-derived suppressor cells (MDSCs). SIGLEC15 inhibited T cell activation by reducing NFAT1, NFAT2, and NF-κB signals. Blocking SIGLEC15 increased the secretion of IFN-γ and IL-2 in vitro and in vivo. In conclusion, our finding demonstrates that SIGLEC15 is an emerging and promising target for immunotherapy in ATC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyMembrane ProteinsThyroid Carcinoma, AnaplasticThyroid NeoplasmsAnimalsHumansMiceAntineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesCell Line, TumorImmunoglobulinsLectinsTumor MicroenvironmentXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Anaplastic thyroid cancerImmunotherapySIGLEC15Tumor microenvironmentsingle-cell RNA-sequencing

Substanzen

Antineoplastic Agents, ImmunologicalImmunoglobulinsLectinsMembrane ProteinsSIGLEC15 protein, human

Autor:innen und Institutionen

  • Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 310014, Hangzhou, China.
  • Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
  • Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China; Key Laboratory of Endocrine Gland Diseases of Zhejiang P…
  • Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 310014, Hangzhou, China; Key Lab…

Förderung

  • Zhejiang Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Bao, L., Li, Y., Hu, X., Gong, Y., Chen, J., Huang, P., Tan, Z., Ge, M., & Pan, Z. (2024). Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer. International Immunopharmacology, 133, 112102. https://doi.org/10.1016/j.intimp.2024.112102

Vancouver

Bao L, Li Y, Hu X, Gong Y, Chen J, Huang P, et al. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer. International Immunopharmacology. 2024;133:112102. doi:10.1016/j.intimp.2024.112102

BibTeX
@article{Bao2024,
  author = {Bao, Lisha and Li, Ying and Hu, Xiaoping and Gong, Yingying and Chen, Jinming and Huang, Ping and Tan, Zhuo and Ge, Minghua and Pan, Zongfu},
  title = {Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {133},
  pages = {112102},
  doi = {10.1016/j.intimp.2024.112102}
}
Kostenlos starten →